Background: IDH-wildtype glioblastoma is the most common malignant primary brain tumour in adults. As there is limited information on prognostic factors outside of clinical trials; thus, we conducted a retrospective study to characterise the glioblastoma population at our centre. Methods: Demographic, tumour molecular profiles, treatment, and survival data were collated for patients diagnosed with glioblastoma at our centre between July 2011 and December 2015. We used multivariate proportional hazard model associations with survival. Results: 490 patients were included; 60% had debulking surgery and 40% biopsy only. Subsequently, 56% had standard chemoradiotherapy, 25% had non-standard chemo/radio-therapy, and 19% had no further treatment. Overall survival was 9.2 months. In the multivariate analysis, longer survival was associated with debulking surgery vs. biopsy alone (14.9 vs. 8 months) (HR 0.54 95% CI 0.41−0.70), subsequent treatment after diagnosis (HR 0.12 0.08−0.16) (standard chemoradiotherapy 16.9 months vs. non-standard regimens 9.2 months vs. none 2.0 months), tumour MGMT promotor methylation (HR 0.71 0.58−0.87), and younger age (hazard ratio vs. age < 50: 1.70 1.26−2.30 for ages 50−59; 3.53 2.65−4.70 for ages 60−69; 4.82 3.54−6.56 for ages 70+). Conclusions: The median survival for patients with glioblastoma is less than a year. Younger age, debulking surgery, treatment with chemoradiotherapy, and MGMT promotor methylation are independently associated with longer survival.